Regenxbio Shares Rise on $100 Million Milestone Payment After First Patient Dosed in Eye-Disease Trial
By Doc Louallen
Regenxbio shares advanced after the company said the first patient was dosed in its Phase IIb/III Naavigate study of surabgene lomparvovec for diabetic retinopathy and that it will receive a $100 million milestone payment from AbbVie.
Shares were up 10% at $13.14 in midday trading Wednesday. The stock is up more than 50% over the past three months.
The biotechnology company said the study is testing a one-time, in-office gene therapy for diabetic retinopathy, an eye disease tied to diabetes that can lead to vision loss. The primary endpoint is to assess whether the treatment can improve disease severity by two steps or more on the diabetic retinopathy severity scale at one year, Regenxbio said.
The Phase IIb portion is expected to enroll about 135 participants in the U.S., the company said.
Write to Doc Louallen at Doc.Louallen@wsj.com
(END) Dow Jones Newswires
July 01, 2026 12:44 ET (16:44 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy in August
These 15 Stocks Destroyed the Most Shareholder Value Over the Past Decade
10 Best Growth Stocks to Buy for the Long Term
One Statistician’s Warning for Retirees About the 4% Rule
United States